secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001558370-23-008805
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros Q1 net loss $33.7M; receives $200M milestone; OMS906 data positive in PNH
--------------------------------------------------------------------------------

- Net loss $33.7M ($0.54 per share) vs $33.0M ($0.53) Q1 2022; cash burn $23.6M excl $200M milestone.
- Received $200M milestone from Rayner; OMIDRIA royalties $9.2M on $30.7M sales (down from $13.8M on $27.7M).
- Plans BLA resubmission for narsoplimab in TA-TMA; meeting with FDA this month.
- OMS906 in PNH: mean Hgb increased 3.4 g/dL at day 29; 100% of patients Hgb >=15.7 g/dL at day 113.
- Awarded $6.69M NIDA grant for OMS527 in cocaine use disorder.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000155837023008805/0001558370-23-008805-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000155837023008805/omer-20230509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-008805

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer